AUTL - Autolus Therapeutics Ltd
Autolus Therapeutics Ltd Logo

AUTL - Autolus Therapeutics Ltd

https://www.autolus.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bullish
Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - Autolus Therapeutics ( NASDAQ:AUTL )
Benzinga • 4 months, 3 weeks ago • score: 0.17
LONDON, April 22, 2025 ( GLOBE NEWSWIRE ) -- Autolus Therapeutics plc AUTL, an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its first quarter 2025 financial results and ...
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United Kingdom.

52W High
$5.00
52W Low
$1.11
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.87
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
0.03
EV/Revenue (<3 favorable)
2.36
P/S (TTM) (<3 favorable)
12.98
P/B (<3 favorable)
1.12
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
18.09%
Institutions (25–75% balanced)
84.08%
Shares Outstanding
266,141,000
Float
118,518,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
29,934,000
Gross Profit (TTM)
-154,510,000
EPS (TTM)
-0.87
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-2.93%
ROE (TTM) (>15% strong)
-0.52%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.11
Momentum
Bearish momentum
Value
-0.2268
Previous
-0.2393
Trend
Rising
Signal Cross
No cross
As of
Sep. 11, 2025